FUNDRAISING ANNOUNCEMENTS
GUEST INTERVIEWS
- Anonymous analyst Crémieux: MFN drug pricing will cause 10% US price drop but 90% increase in Canada, threatens pharma R&D
- RA Capital's Tess Cameron: biotech stocks rose on EO because market sees it as trade lever, not price control
- Sweet Capital's Pippa Lamb on UK-US trade deal, European venture gaps, and the Nordics as a tech hub
- Eoghan McCabe on Intercom's AI agent Fin: resolution-based pricing is the future, growth rate doubling three years running
- BoxGroup's David Tisch on AI M&A, brand moats, and being a seed investor in Cursor and Clay
- PillPack founder TJ Parker: drug pricing debate is distorted by list vs. net price confusion, EO's most promising element is direct consumer pricing reform